19 results about "Citrate buffer" patented technology

The application discloses a cysteine-rich protein 61 antigen storage solution, which comprises a protein protective agent, a non-ionic surfactant, a preservative, a soluble metal salt, a sugar substance and a buffer solution, wherein the buffer solution is a citric acid-citrate buffer solution, and the storage solution further comprises polyethylene glycol and polyvinylpyrrolidone; the pH value of the storage solution is in the range of 5.0-5.5; the added mass of the polyvinylpyrrolidone is 1.0-1.5 times of the mass of the polyethylene glycol; and the protein protective agent at least contains serum. The storage solution can stably store the cysteine-rich protein 61 antigen, and the cysteine-rich protein 61 antigen can be stably stored for 12 months at 2-8 DEG C and for 7 days at 37 DEG C, thereby solving the inconvenience caused by the freeze-drying storage of Cyr61 protein due to the stability and providing important support for Cyr61 as a new marker for subsequent clinical application.

The invention relates to the field of biomedical technologies and pharmaceutical preparations, and discloses a TLR9 + HA201 composite adjuvant and a preparation method and application thereof, and the TLR9 + HA201 composite adjuvant freeze-drying preparation comprises the following components: a TLR9 + HA201 composite adjuvant, a TLR9 + HA201 composite adjuvant, a TLR9 + HA201 composite adjuvant freeze-drying agent, a TLR9 + HA201 composite adjuvant freeze-drying agent, a TLR9 D-(+)-trehalose; l-glutamic acid; a citrate buffer solution; the pH value of the aqueous solution to be freeze-dried is 6.5-7.5, the concentration of the D-(+)-trehalose is 8% w / v-12% w / v, the concentration of the L-glutamic acid is 0.8% w / v-1. 5% w / v, and the concentration of the citrate buffer solution is 15-25 mM. Through the synergistic effect of D-(+)-trehalose and L-glutamic acid in a specific citrate buffer system, efficient protection on the biological activity of the TLR9 + HA201 composite adjuvant is achieved, and the freeze-dried preparation shows the immune activation ability basically consistent with that before freeze-drying after being redissolved.

The present invention provides a formulation that includes a therapeutically effective amount of phenylephrine or a pharmaceutically acceptable salt thereof, and a method for preparing the formulation. In some embodiments, the formulation includes a tonicity agent, a citrate buffer, water, and has an initial pH of from 5.6 to 6.0. In other embodiments, the formulation includes a tonicity agent, a citrate buffer, an antioxidant, water, and has an initial pH of from 3.6 to 4.8. The formulation of the invention is sterile, stable, ready-to-administer and packaged into a polymeric syringe.

The invention discloses a nano iron oxide injection based on a synergistic stabilization mechanism and a preparation method of the nano iron oxide injection. The injection comprises nano iron oxide particles, carboxyl-terminated methoxypolyethylene glycol, an amino acid stabilizer, a citrate buffer agent and an isotonic agent. The preparation method comprises the following steps: synthesizing an oleic acid modified nano iron oxide core; performing ligand exchange at 0-4 DEG C to form a PEG anchoring layer; then, under the temperature of 6-8 DEG C, through programmed feeding and low-temperature shearing, amino acid and citrate are synergistically embedded, and a stable structure is constructed. According to the invention, a triple stable system of PEG anchoring layer-synergistic chelating layer-buffer microenvironment is constructed, and a whole-course low-temperature controllable process is adopted, so that the defects of poor long-term stability, high iron ion release rate, poor process reproducibility and poor moist heat sterilization resistance of the existing nano iron oxide contrast agent are overcome. The obtained product has excellent colloidal stability, extremely low ion release rate and good biological safety, and is suitable for magnetic resonance imaging.

The present application relates to a kind of cordyceps militaris extract and its extraction process, belong to traditional Chinese medicine extraction technical field.The present application is through enzymolysis, pulse ultrasonic and supercritical extraction synergistic effect to improve extraction efficiency.Specifically including: cordyceps militaris raw materials and cellulase, pectinase mixed enzymolysis, under the protection of inert gas, adding the protective agent containing glutathione and ascorbic acid and ethanol-citrate buffer solution is treated by pulse ultrasonic;Extract liquid is concentrated after supercritical CO2 extraction removes fat-soluble impurities, freeze-drying obtains extract.The obtained extract cordycepin content is ≥0.8%, and the mass ratio of cordycepin and cordycepic acid is stably at 1:0.2-1.The process solves the problem of serious damage of active ingredient in traditional method, low efficiency.

The application relates to the technical field of biological pharmacy, and discloses a preparation method of a ready-to-use stable 3D-MLA adjuvant solution, which comprises the following steps: dissolving citric acid monohydrate and trisodium citrate dihydrate in water for injection to prepare a citrate buffer; under stirring, adding polysorbate 80 into the citrate buffer to dissolve the polysorbate 80; under stirring, adding 3D-MLA into the obtained solution to dissolve the 3D-MLA; adjusting the pH value of the solution; using water for injection to fix the volume; performing sterilization filtration through a filter membrane, filling the filtrate into a container and sealing the container; and cold storage. Through the citrate buffer and the adjustment of the pH value of the adjuvant solution, the combination of the buffer system and the pH environment effectively inhibits the chemical degradation of the 3D-MLA in the water for injection, the technical problem that the solution is prone to degradation is solved, and a ready-to-use preparation which can be stably stored under cold storage conditions is obtained.

The present invention relates to a pharmaceutical composition comprising a radiohybrid agent containing silicon fluoride and a chelating group wherein the fluorine is 18F or the chelating group contains a chelated radioactive metal, wherein the composition has a pH of 4.0-6.0 and further comprises: 0.1-200 mM citrate buffer; 1-100 mg / mL ethanol; and 5-10 mg / mL sodium chloride.

An improved adenovirus formulation comprising: a) a recombinant adenovirus; b) a citrate buffer; c) a cyclodextrin compound; and d) a salt, said formulation having a pH ranging from about 5.5 to about 6.5, and wherein said formulation is free of non-ionic detergent. The invention also relates to a method of preserving an adenovirus which comprises preparing said formulation.

The invention provides a pharmaceutical composition for preventing and / or treating tetanus as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises a recombinant tetanus toxin C fragment as a unique antigen component, an adjuvant and a solvent, wherein the adjuvant is selected from one or more of an aluminum adjuvant, a Toll-like receptor stimulant and saponin, preferably the aluminum adjuvant, and / or the solvent is selected from one or more of a phosphate buffer solution, a citrate buffer solution, a histidine salt buffer solution and a sodium chloride solution, preferably the phosphate buffer solution and / or the sodium chloride solution. The adopted recombinant tetanus natural C fragment (Hc) is non-toxic, formaldehyde inactivation is not needed, meanwhile, the possibility of toxicity reversion is avoided, and the pharmaceutical composition can induce mammals to generate high immune response against tetanus and has good immune persistence.

A detergent may include a citrate buffer. A detergent may include a surfactant component. A detergent may include a chelator component, wherein a pH of the detergent composition is in a range of from about 6.5 to about 9, and at least one of the citrate buffer, surfactant component and the chelator component are biodegradable.

Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.

A composition containing levosimendan, one or more solubilizing and / or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and / or stabilizing agents may be a cyclodextrin or a cyclodextrin derivative. The cyclodextrin derivative may be a derivative of an alpha-cyclodextrin, or beta-cyclodextrin, or a gamma-cyclodextrin. The cyclodextrin derivative may contain a butyl ether spacer group, an alkyl ether space group, or both. The one or more additional pharmaceutically acceptable additives may be a non-citrate buffer. The composition may be used in a method of treating a health condition, such as heart failure, pulmonary hypertension, chronic kidney disease, amyotrophic lateral sclerosis, stroke, in advance of a planned cardiac surgery, or other health conditions for which a minimally invasive or repeated administration of levosimendan may be beneficial. The composition may be administered subcutaneously.

This invention relates to the field of protein extraction technology, specifically disclosing a method for the simultaneous co-production and extraction of egg white lysozyme and ovotransferrin, comprising: (1) Egg white pretreatment: after dilution, adjust the pH to 4.5, filter out the ovomucin precipitate, and then adjust the supernatant to pH 8.0-9.0. (2) Cation exchange separation of lysozyme: adsorb onto a cation exchange column of the pretreatment solution, collect the permeate and eluent as the egg white flow-through solution; elute the lysozyme, and obtain the lysozyme product by concentration, desalting, sterilization, and drying. (3) Anion exchange separation of ovotransferrin: after adjusting the flow-through solution to pH 5.5-6.0, load onto an anion exchange column, elute to remove impurities, and collect the permeate containing ovotransferrin. (4) Iron removal and drying: concentrate by ultrafiltration, dialyze with citrate buffer for desalting and preliminary iron removal, then remove bound iron by chelating resin, and dry to obtain the iron-free ovotransferrin product.

Provided is a liquid preparation containing an anti-IL-17 antibody at a concentration of 20 mg / mL to 200 mg / mL, a citrate buffer at a concentration of 10 mM to 50 mM, a sucrose at a concentration of 20 mg / mL to 120 mg / mL or arginine at a concentration of 50 mM to 250 mM, and polysorbate 80 at a concentration of 0.1 mg / mL to 5 mg / mL. In addition, the liquid preparation has a pH of 6.0±0.5, wherein the anti-IL-17 antibody is an anti-IL-17A / F monoclonal antibody. The liquid preparation can be a stable subcutaneous injection preparation, and can be used to treat IL-17A and / or IL-17F related diseases, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, osteoarthritis or inflammatory bowel disease.

Provided herein are drug products adapted for nasal delivery comprising a device and a pharmaceutical composition comprising an opioid receptor antagonist, wherein the claimed invention provides a unit dose of an aqueous pharmaceutical solution, or aqueous pharmaceutical composition, housed in a device configured for intranasal administration to a patient, wherein the aqueous pharmaceutical solution consists of, or the aqueous pharmaceutical composition consists essentially of: (i) naloxone hydrochloride in an amount of about 9% by weight based on the total weight of the aqueous pharmaceutical solution; (ii) glycerin in an amount of about 1.4% by weight based on the total weight of the aqueous pharmaceutical solution; (iii) a citrate buffer system adjusted by hydrochloric acid and / or sodium hydroxide; and (iv) United States Pharmacopeia (USP)-grade Purified Water; wherein the pH of the aqueous pharmaceutical solution is from about 3.5 to about 4.7; and wherein the hydrochloric acid and the sodium hydroxide may each be independently present in the aqueous pharmaceutical solution, as required, to achieve the pH from about 3.5 to about 4.7.

Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.

This invention provides a method for producing microencapsulated activators that are robust, protect encapsulated probiotic bacteria, and have storage stability. [Solution] The method comprises the steps of preparing a protein suspension containing denatured plant protein, preparing a suspension of hydrated probiotics, mixing the protein suspension and the hydrated probiotics suspension to encapsulate the probiotics in a denatured pea protein matrix, and polymerizing the denatured plant protein matrix with calcium salts. The mixing step may include extruding the protein suspension and the hydrated probiotics suspension to form microdroplets, and the polymerization step includes curing the extruded microdroplets in a curing bath containing calcium citrate buffer having a pH of 6.5 and a molar concentration of 0.05 to 0.15 M.

This invention belongs to the field of veterinary drug formulation technology, specifically relating to a water-soluble tilmicosin premix and its preparation method. Its composition includes the following raw materials: tilmicosin phosphate, citric acid, tartaric acid, polyvinylpyrrolidone K30, sulfobutyl-β-cyclodextrin, citrate buffer pair, sodium gluconate, tetrasodium diacetate of glutamate, alkylated hydroxypropyl methylcellulose, binuclear seeds, mannitol, microcapsule NaHCO3, fumed silica, and lecithin. This invention first uses citric acid, tartaric acid, and PVP to co-amorphize and spray-dry tilmicosin phosphate to prepare a masterbatch, improving solubility and reducing recrystallization tendency; then, it sprays an inner layer containing sulfobutyl-β-cyclodextrin, etc., followed by a GLDA chelating layer, a modified cellulose hydrophilic membrane, a binuclear carrier, mannitol isolation, microcapsule NaHCO3, an outer layer of lecithin, and fumed silica to optimize dissolution and stability.

The present invention relates to a new multifunctional debridement and / or antifouling composition comprising sodium fluoride (NaF), poloxamer, and a phosphate citrate buffer, wherein the composition is in liquid form at room temperature, such as at a temperature of at the most 20°C and has a pH of approximately pH 5.5. The composition disclosed herein is antimicrobial, bacteriostatic, pro-resolution and / or anti-inflammatory and is particularly useful in cleaning and / or debriding a biological surface and or a biomaterial surface in situ, such as for use in cleaning and / or debriding implants, dental prosthetics and / or teeth. It can be used for removal of calculus, prophylactic use and / or as a cosmetic composition.